Skye Bioscience (SKYE) Enterprise Value Growth (3y) (2017 - 2026)
Skye Bioscience (SKYE) Enterprise Value Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,450.94% |
| Dec 31, 2025 | -1,677.86% |
| Sep 30, 2025 | -1,876.41% |
| Jun 30, 2025 | -2,098.37% |
| Mar 31, 2025 | -2,248.54% |
| Sep 30, 2024 | -2,352.50% |
| Jun 30, 2024 | -142.68% |
| Mar 31, 2024 | -2,532.77% |
| Sep 30, 2023 | -1,160.33% |
| Jun 30, 2023 | -75.42% |
| Mar 31, 2023 | 79.89% |
| Dec 31, 2022 | -0.31% |
| Sep 30, 2022 | 84.87% |
| Jun 30, 2022 | 88.23% |
| Mar 31, 2022 | 89.88% |
| Sep 30, 2021 | 83.72% |
| Jun 30, 2021 | -40.38% |
| Mar 31, 2021 | 88.43% |
| Sep 30, 2020 | 52.36% |
| Jun 30, 2020 | 1.98% |